Epigenomics AG (EPGNF)
USD 0.79
(0.0%)
USD 0.79
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.61 Million EUR | 67.8% |
| 2022 | -11.22 Million EUR | -480.85% |
| 2021 | -1.93 Million EUR | 82.55% |
| 2020 | -11.07 Million EUR | 20.84% |
| 2019 | -13.99 Million EUR | -11.28% |
| 2018 | -12.57 Million EUR | -24.58% |
| 2017 | -9.93 Million EUR | 15.46% |
| 2016 | -11.94 Million EUR | -39.24% |
| 2015 | -8.57 Million EUR | -13.5% |
| 2014 | -7.59 Million EUR | -17.74% |
| 2013 | -6.44 Million EUR | 42.24% |
| 2012 | -11.12 Million EUR | -1.54% |
| 2011 | -10.93 Million EUR | -6.27% |
| 2010 | -10.3 Million EUR | -11.44% |
| 2009 | -9.23 Million EUR | 2.99% |
| 2008 | -9.52 Million EUR | -243.25% |
| 2007 | -11.62 Million EUR | -28.79% |
| 2006 | 9.33 Million EUR | -21.62% |
| 2005 | 11.9 Million EUR | 5.27% |
| 2004 | 11.31 Million EUR | 48.37% |
| 2003 | 7.62 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - EUR | 67.8% |
| 2023 Q4 | 2.3 Million EUR | -10.14% |
| 2023 Q2 | -2.11 Million EUR | 51.13% |
| 2023 Q1 | -4.32 Million EUR | 32.13% |
| 2023 Q3 | 2.56 Million EUR | 221.42% |
| 2022 Q3 | -1.3 Million EUR | -27.72% |
| 2022 Q1 | -2.52 Million EUR | -52.44% |
| 2022 Q4 | -6.36 Million EUR | -388.34% |
| 2022 FY | - EUR | -480.85% |
| 2022 Q2 | -1.02 Million EUR | 59.63% |
| 2021 Q3 | 2.9 Million EUR | 230.15% |
| 2021 Q4 | -1.65 Million EUR | -157.11% |
| 2021 FY | - EUR | 82.55% |
| 2021 Q1 | -954 Thousand EUR | 60.72% |
| 2021 Q2 | -2.23 Million EUR | -133.96% |
| 2020 FY | - EUR | 20.84% |
| 2020 Q3 | -2.6 Million EUR | 18.91% |
| 2020 Q1 | -2.82 Million EUR | 23.69% |
| 2020 Q2 | -3.21 Million EUR | -13.96% |
| 2020 Q4 | -2.42 Million EUR | 6.86% |
| 2019 FY | - EUR | -11.28% |
| 2019 Q1 | -3.15 Million EUR | 20.03% |
| 2019 Q2 | -4.47 Million EUR | -41.88% |
| 2019 Q3 | -2.66 Million EUR | 40.49% |
| 2019 Q4 | -3.69 Million EUR | -38.87% |
| 2018 Q3 | -2.95 Million EUR | -18.37% |
| 2018 FY | - EUR | -24.58% |
| 2018 Q1 | -3.17 Million EUR | -84.73% |
| 2018 Q2 | -2.49 Million EUR | 21.17% |
| 2018 Q4 | -3.94 Million EUR | -33.33% |
| 2017 FY | - EUR | 15.46% |
| 2017 Q1 | -2.61 Million EUR | -74.77% |
| 2017 Q3 | -1.11 Million EUR | 75.11% |
| 2017 Q2 | -4.48 Million EUR | -71.43% |
| 2017 Q4 | -1.71 Million EUR | -53.63% |
| 2016 Q2 | -3.44 Million EUR | 23.57% |
| 2016 FY | - EUR | -39.24% |
| 2016 Q4 | -1.49 Million EUR | 41.09% |
| 2016 Q3 | -2.54 Million EUR | 26.08% |
| 2016 Q1 | -4.5 Million EUR | -416.17% |
| 2015 Q3 | -2.39 Million EUR | -1.01% |
| 2015 Q4 | -872 Thousand EUR | 63.51% |
| 2015 Q2 | -2.36 Million EUR | 19.85% |
| 2015 Q1 | -2.95 Million EUR | -7.7% |
| 2015 FY | - EUR | -13.5% |
| 2014 Q1 | -1.8 Million EUR | 2.96% |
| 2014 FY | - EUR | -17.74% |
| 2014 Q4 | -2.74 Million EUR | -73.15% |
| 2014 Q3 | -1.58 Million EUR | -11.17% |
| 2014 Q2 | -1.42 Million EUR | 21.06% |
| 2013 Q2 | -1.38 Million EUR | 9.41% |
| 2013 Q3 | -1.65 Million EUR | -19.05% |
| 2013 Q4 | -1.85 Million EUR | -12.67% |
| 2013 FY | - EUR | 42.24% |
| 2013 Q1 | -1.53 Million EUR | 38.08% |
| 2012 Q2 | -3.23 Million EUR | -61.02% |
| 2012 FY | - EUR | -1.54% |
| 2012 Q1 | -2 Million EUR | -15.29% |
| 2012 Q3 | -3.47 Million EUR | -7.68% |
| 2012 Q4 | -2.47 Million EUR | 28.95% |
| 2011 FY | - EUR | -6.27% |
| 2011 Q1 | -2.7 Million EUR | -11.66% |
| 2011 Q2 | -2.78 Million EUR | -3.3% |
| 2011 Q3 | -3.83 Million EUR | -37.33% |
| 2011 Q4 | -1.74 Million EUR | 54.57% |
| 2010 Q1 | -2.42 Million EUR | 18.38% |
| 2010 Q4 | -2.41 Million EUR | 14.13% |
| 2010 Q3 | -2.81 Million EUR | -6.79% |
| 2010 Q2 | -2.63 Million EUR | -8.79% |
| 2010 FY | - EUR | -11.44% |
| 2009 Q3 | -1.94 Million EUR | 13.21% |
| 2009 FY | - EUR | 2.99% |
| 2009 Q1 | -2.08 Million EUR | 0.0% |
| 2009 Q2 | -2.24 Million EUR | -7.64% |
| 2009 Q4 | -2.97 Million EUR | -52.7% |
| 2008 FY | - EUR | -243.25% |
| 2007 FY | - EUR | -28.79% |
| 2006 FY | - EUR | -21.62% |
| 2005 FY | - EUR | 5.27% |
| 2004 FY | - EUR | 48.37% |
| 2003 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | -210.708% |
| Arrayit Corporation | -3.07 Million USD | -17.418% |
| Atlantic International Corp. | -5.38 Million USD | 32.953% |
| Biocept, Inc. | -30.24 Million USD | 88.051% |
| Bioqual, Inc. | 3.03 Million USD | 219.171% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | -377.114% |
| DermTech, Inc. | -97.89 Million USD | 96.309% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 100.124% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 82.149% |
| iMD Companies, Inc. | -154.65 Thousand USD | -2236.456% |
| IDenta Corp. | 71.58 Thousand USD | 5147.759% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 194.176% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 9439.723% |
| InVitro International | 6680.00 USD | 54194.895% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 33.526% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | -29680.279% |
| Medical Imaging Corp. | -896.74 Thousand USD | -302.963% |
| NovelStem International Corp. | -3.78 Million USD | 4.55% |
| Optigenex Inc. | -1.18 Million USD | -204.497% |
| PharmChem, Inc. | 1.05 Million USD | 442.902% |
| Proteome Sciences plc | -1.13 Million USD | -217.813% |
| Response Genetics, Inc | -19.66 Million USD | 81.625% |
| Rennova Health, Inc. | -234.81 Thousand USD | -1438.888% |
| RushNet, Inc. | -614.85 Thousand USD | -487.709% |
| ScreenPro Security Inc. | -3.43 Million USD | -5.201% |
| Stella Diagnostics Inc. | -5.7 Million USD | 36.687% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 64.815% |
| Todos Medical Ltd. | -9.39 Million USD | 61.534% |